Q-omics provides the consensus-scored ADAM2 profile across patient tissues and cancer cell-line models. ADAM2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ADAM2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADAM2 protein abundance shows 18,614 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, KIRC, and PDAC as cancer lineages where ADAM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM2 survival associations across molecular data types. ADAM2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM2 RNA expression–survival associations across cancer types. High ADAM2 expression shows unfavorable associations in LIHC, KIRC, BRCA and KICH, but favorable associations in ACC and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ADAM2 RNA expression.
This table summarizes ADAM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADAM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM2 shows lower tumor expression in KIRC and higher tumor expression in HNSC, KICH, LUAD, PRAD and UCEC. The KIRC box plot shows higher ADAM2 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p < 0.001).
This table shows molecular features associated with ADAM2 in patient tissues and cancer cell lines. In patient samples, ADAM2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
